TBPH Theravance Biopharma Inc.

22.56
-0.73  -3%
Previous Close 23.29
Open 23.54
Price To Book -6.36
Market Cap 1,421,331,911
Shares 63,002,301
Volume 178,577
Short Ratio
Av. Daily Volume 506,066
Stock charts supplied by TradingView

NewsSee all news

  1. Theravance Biopharma Announces Closing of Private Placement of $400 Million Non-Recourse Notes

    DUBLIN, March 2, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) ("Theravance Biopharma" and together with its subsidiaries, the "Company"), a diversified biopharmaceutical company primarily

  2. Theravance Biopharma, Inc. Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update

    DUBLIN, Feb. 24, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today reported financial results for the fourth quarter and full year ended

  3. Theravance Biopharma Announces Presentations at Upcoming Investor Conferences

    DUBLIN, Feb. 18, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines,

  4. Theravance Biopharma to Report Fourth Quarter and Full Year 2019 Financial Results on February 24, 2020

    DUBLIN, Feb. 13, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines,

  5. Theravance Biopharma Announces Pricing of Public Offering of Ordinary Shares

    DUBLIN, Feb. 11, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data released September 20, 2017 - primary endpoint met.
Closed Triple - IMPACT
COPD
Approved June 21, 2013.
VIBATIV (telavancin hydrochloride) for injection
Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP)
Approved April 30, 2015.
BREO ELLIPTA
Asthma
Phase 3 data due late-2020.
Ampreloxetine (TD-9855)
nOH
sNDA filing announced October 2, 2019. PDUFA date 2Q 2020. Estimate August 2, 2020 using 10-month timeline.
Closed Triple - CAPTAIN
Asthma
Approval announced September 19, 2017.
Closed Triple
COPD
FDA Approval announced November 9, 2018.
Revefenacin
COPD
Phase 2b data released August 2, 2017. Primary endpoint not met.
Velusetrag (TD-5108)
Gastroparesis
Phase 2 data released June 2016
TD-6450
Hepatitis C virus (HCV)
Phase 3 trial discontinued following recent interim analysis.
Telavancin
Bacteremia
Phase 3 first patient enrolled late February 2015. Data due 2017
Telavancin
Staphylococcus aureus bacteremia
Phase 2 data due late-2020.
TD-1473
Crohn's Disease
Phase 2b data due late-2020.
TD-1473
Ulcerative Colitis
Phase 1 Part C data due mid-2020.
TD-8236
Asthma
Phase 2 data due mid-2020.
TD-8236
Asthma

Latest News

  1. Theravance Biopharma Announces Closing of Private Placement of $400 Million Non-Recourse Notes

    DUBLIN, March 2, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) ("Theravance Biopharma" and together with its subsidiaries, the "Company"), a diversified biopharmaceutical company primarily

  2. Theravance Biopharma, Inc. Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update

    DUBLIN, Feb. 24, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today reported financial results for the fourth quarter and full year ended

  3. Theravance Biopharma Announces Presentations at Upcoming Investor Conferences

    DUBLIN, Feb. 18, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines,

  4. Theravance Biopharma to Report Fourth Quarter and Full Year 2019 Financial Results on February 24, 2020

    DUBLIN, Feb. 13, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines,

  5. Theravance Biopharma Announces Pricing of Public Offering of Ordinary Shares

    DUBLIN, Feb. 11, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery,

  6. Theravance Biopharma Announces Proposed Public Offering of Ordinary Shares

    DUBLIN, Feb. 10, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery,

  7. Theravance Biopharma Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference

    DUBLIN, Jan. 7, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines,

  8. Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program

    DUBLIN and NEW YORK, Dec. 23, 2019 /PRNewswire/ -- Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (NASDAQ:TBPH) ("Theravance Biopharma") and Pfizer Inc. (NYSE:PFE)

  9. Theravance Biopharma Announces Dosing of First Patient in Phase 2 Allergen Challenge Study of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases

    DUBLIN, Dec. 3, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase 2 allergen challenge study of

  10. Theravance Biopharma to Present at Two Upcoming Investor Conferences

    DUBLIN, Nov. 26, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) announced today that management will participate in fireside chats at two upcoming investor conferences:

  11. Theravance Biopharma to Present at the 2019 Credit Suisse Healthcare Conference

    DUBLIN, Nov. 6, 2019 /PRNewswire/ -- November 6, 2019 – Theravance Biopharma, Inc. (NASDAQ:TBPH) announced today that management will participate in a corporate presentation at the 28th Annual Credit Suisse Healthcare

  12. Theravance Biopharma to Present at the 2019 Cantor Global Healthcare Conference

    DUBLIN, Sept. 25, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) announced today that management will participate in a fireside chat at the 2019 Cantor Global Healthcare Conference on Thursday, October 3,

  13. Theravance Biopharma Reports Positive Results from Phase 1 Clinical Trial of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases

    DUBLIN, Sept. 9, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) ("Theravance Biopharma" or the "Company") today announced initial results, including positive biomarker responses, from its

  14. Theravance Biopharma to Present at Two Upcoming Investor Conferences

    DUBLIN, Aug. 28, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) announced today that members of management will participate in fireside chats at two upcoming investor conferences: 14th Annual Wells Fargo